Eli Lilly beats 2Q forecasts
INDIANAPOLIS - Core medicines Zyprexa and Cymbalta helped Eli Lilly and Co. beat Wall Street’s second-quarter expectations, although profits fell 19 percent at the tablet tadalafil
company because of acquisition costs. […]